Search
Elicio Therapeutics Inc
ELTXAdd to Watchlist
3.175USD
+0.035+1.11%
Close 08-07 16:00（ET）Quotes delayed by 15 min
56.52MMarket Cap
LossP/E TTM
Forecast
Currency: USD Updated: 2026-08-07The current earnings forecast score of Elicio Therapeutics Inc is 8.00, ranking 171 out of 387 in the Biotechnology & Medical Research industry. The average price target is 15.50, with a high of 18.00 and a low of 13.00.
Analyst Rating
Based on
4
analysts
Buy
Current Rating
20.000
Target Price
+532.91%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
497
Total
6
Median
7
Average
Company name
Ratings
Analysts
Elicio Therapeutics Inc
ELTX
4
Beigene Ltd
ONC
28
argenx SE
ARGX
26
Ionis Pharmaceuticals Inc
IONS
25
Insmed Inc
INSM
24
Kymera Therapeutics Inc
KYMR
23
1
2
3
...
100
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Elicio Therapeutics Inc's price target?
Analysts forecast that Elicio Therapeutics Inc's price target is USD 15.50, with the highest forecast at USD 18.00 and the lowest forecast at USD 13.00.
How have Elicio Therapeutics IncELTX's recent earnings per share performed?
The market expectation was USD -0.65, while Elicio Therapeutics IncELTX's earnings per share (EPS) for the previous quarter was USD -0.50. EPS for the next quarter is expected at USD -0.54.
What is the analyst rating for Elicio Therapeutics Inc?
Based on the ratings of Elicio Therapeutics Inc's stock from 4 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.